Inhibikase Therapeutics, Inc. Quarterly report [Sections 13 or 15(d)]

Liquidity - Additional Information (Details) - USD ($)	1 Months Ended							6 Months Ended	12 Months Ended
Liquidity - Additional Information (Details) - USD ($)	Jul. 31, 2026	Nov. 30, 2025	Oct. 31, 2024	May 31, 2024	Jan. 31, 2023	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2026	Dec. 31, 2024	Dec. 31, 2025
DisclosureOfGoingConcernLineItems
Cash, cash equivalents and marketable securities								$ 159,000,000
Accumulated deficit								(178,651,871)		$ (142,679,800)
ATM Agreement [Member]
DisclosureOfGoingConcernLineItems
Gross proceeds from agent (Private Placement)								2,900,000	$ 500,000
Issuance of common stock, Shares	25,261,500
RA Capital Management [Member]
DisclosureOfGoingConcernLineItems
Gross proceeds from agent (Private Placement)								$ 49,200,000
Issuance of common stock, Shares	25,000,000
Private Placement [Member] \| ATM Agreement [Member] \| Common Stock
DisclosureOfGoingConcernLineItems
Gross proceeds from agent (Private Placement)		$ 107,600,000	$ 99,600,000	$ 3,200,000	$ 8,500,000	$ 41,100,000	$ 14,600,000

Amount of accumulated undistributed earnings (deficit).